Tscan Therapeutics, Inc. · NASDAQ:TCRX
Tscan Therapeutics — Technical Presentation (June 2026)
65 slides from Tscan Therapeutics's technical presentation, Jun 22, 2026
Slide 1: Data from Cohort C of the Phase 1 ALLOHA Study
Data from Cohort C of the Phase 1 ALLOHA™ Study June 2026 Exhibit 99.2
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.’
Slide 3: TScan is a fully integrated, next-generation TCR-T cell therapy company
TScan is a fully integrated, next-generation TCR-T cell therapy company HEME MALIGNANCY PROGRAM Designed to treat residual disease and prevent relapse in patients undergoing bone marrow transplant TSC-101 continues to be well-tolerated Durable long-term data for TSC-101: 100% (2/2) of patients 3-yea
Slide 4: Agenda
Agenda Overview of Heme Program and Manufacturing Update Gavin MacBeath, Ph.D. Updated Data from Cohort C of Phase 1 ALLOHA™ Trial Gavin MacBeath, Ph.D., Ran Reshef, M.D., M.Sc. Phase 3 Trial Design (ALLOHA-2) Chrystal Louis, M.D., M.P.H. Market Opportunity for TSC-101 and Follow-on Product Candidat
Slide 5: Heme Malignancies: Targeting residual disease to prevent relapse
Heme Malignancies: Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 6: TScan is working to treat residual disease and prevent relapse in heme malignancies
TScan is working to treat residual disease and prevent relapse in heme malignancies Current Standard of Care Unmet Medical Need TScan Approach Allogeneic hematopoietic cell transplant (Allo-HCT) is the only potential cure for patients with AML and MDS 38-44% of patients relapse within two years foll
Slide 7: TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer
TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer and prevent relapse following Allo-HCT TSC-101 PATIENT TSC-101 DONOR Hematopoietic cell transplant Cancer cell Normal blood cell Stem cell T cell HA-2 positive HA-2 negative HA-2 negative HA-2 positive TSC-101 Residual cancer Stem
Slide 8: Heme Program: TSC-101 Recap of ASH data
Heme Program: TSC-101 Recap of ASH data
Slide 9: ALLOHA, a multi-arm Phase 1 trial for TSC-101
ALLOHA™, a multi-arm Phase 1 trial for TSC-101 in subjects with AML, ALL, and MDS (NCT05473910) HCT Pre-transplant screening Endpoint and safety monitoring RIC Day 0 Day +21 Day +61 Donor screening Manufacturing apheresis HCT apheresis TSC-101 Infusion 1 TSC-101 Infusion 2 Subject screening Control
Slide 10: Patients treated with TSC-101 have more durable remissions than control patients
Patients treated with TSC-101 have more durable remissions than control patients Control-1 Control-2 Control-3 Control-8 Control-5 Control-4 Control-6 Control-9 Control-10 Control-11 Control-12 Control-13 Control-14 Control-15 Control-16 Control-17 Control-18 Arm TSC-101 DL 1 TSC-101 DL2‡ TSC-101 DL
Slide 11: ALLOHA Phase 1 data support launch of pivotal trial in Q2 2026
ALLOHA™ Phase 1 data support launch of pivotal trial in Q2 2026 Infusions with TSC-101 were well-tolerated with no DLTs and adverse events following HCT + TSC-101 were consistent with HCT alone* TSC-101 identified in all treated patients, including those 3-years post HCT Attractive safety profile Lo
Slide 12: Heme Program Update: Cohort C commercial ready process
Heme Program Update: Patients infused with TSC-101 manufactured with commercial ready process (Cohort C)
Slide 13: Optimized manufacturing process results in robust production with shorter time and lower COGs
Optimized manufacturing process results in robust production with shorter time and lower COGs Phase 1 Process: 17 Days Commercial-ready Process: 12 Days Isolate PBMCs Electro-porate Activate T-cells Expand T-cells Harvest & Freeze Enrich TCR-T cells DAY 1 DAY 2 DAY 6 DAY 9 DAY 17 Isolate PBMCs Elect
Slide 14: Patients are generally well balanced across arms
Patients are generally well balanced across arms, although Cohort C included a higher percentage of patients with MRD-positive disease prior to transplant TSC-101 Cohort A TSC-101 Cohort C Control Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (6
Slide 15: TSC-101 continues to be well-tolerated in Cohort C
TSC-101 continues to be well-tolerated in Cohort C TSC-101 Cohort C n=14 Control* n=19 Treatment-emergent aGvHD (MAGIC) 2 (14%) 12 (63%) Grade I 1 (7%) 6 (32%) Grade II 1 (7%) 5 (26%) Grade III 0 1 (5%) Any Treatment-emergent cGvHD (NIH) 1 (7%) 2 (11%) Mild 1 (7%) 1 (5%) Moderate 0 1 (5
Slide 16: TSC-101 is designed to eliminate residual cancer and prevent relapse following Allo-HCT
TSC-101 is designed to eliminate residual cancer and prevent relapse following Allo-HCT Residual cancer cell (HA-2 positive) Residual nonmalignant cell (HA-2 positive) Normal, donor-derived blood cell (HA-2 negative) Post-transplant patient TCR-T cell infusion TSC-101 T-cell HA-2 TCR TSC-101
Slide 17: Donor chimerism serves as an early surrogate of efficacy
Donor chimerism serves as an early surrogate of efficacy Malignant, patient-derived blood cell Nonmalignant, patient-derived blood cell Normal, donor-derived blood cell Post-transplant patient Normal, donor-derived blood cell Complete donor chimerism (low risk of relapse1,2) Mixed donor chimerism (i
Slide 18: Complete donor chimerism at two months predicts low probability of relapse
Patients with complete donor chimerism using NGS chimerism assay at two months post-transplant have a low probability of relapse Data on file; Data as of May 19, 2026 Chimerism status of initial ALLOHA patients at 2 months post-transplant predicts probability of relapse (HR 10.2) Mixed donor chimeri
Slide 19: 93% of Cohort C patients responded with decreasing recipient chimerism
All but one patient in Cohort C (93%) responded to TSC-101 with decreasing recipient chimerism % recipient chimerism % recipient chimerism Donor chimerism results using investigational next-generation sequencing assay (Alloheme) with data cut-off of 0.2% at indicated times post-transplant (# ± 3 day
Slide 20: 11 of 14 patients achieved complete donor chimerism within ~3 weeks
04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 16-003 27-004 13-017 13-019 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 27-004 16-003 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 11 of 14 patients achieved complete donor chimerism within ~3 weeks of
Slide 21: 11 of 14 patients achieved complete donor chimerism within ~3 weeks
04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 16-003 27-004 13-017 13-019 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 27-004 16-003 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 11 of 14 patients achieved complete donor chimerism within ~3 weeks of
Slide 22: Patient with incomplete chimerism showed stabilization following third infusion
Patient with incomplete chimerism at day 105 showed stabilization following third infusion DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo AML-p53 MDS AML AML ALL-p53 MDS-p53 AML MDS AML MDS AML AML MDS AML Prior
Slide 23: Patient with increasing recipient chimerism shows no morphologic evidence of disease
Patient with increasing recipient chimerism shows no morphologic evidence of disease by bone marrow biopsy DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo AML-p53 MDS AML AML ALL-p53 MDS-p53 AML MDS AML MDS AML AM
Slide 24: Patient with p53-mutated ALL shows steady decrease in recipient chimerism
Patient with p53-mutated ALL shows steady decrease in recipient chimerism DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo AML-p53 MDS AML AML ALL-p53 MDS-p53 AML MDS AML MDS AML AML MDS AML Prior to infusion × × ×
Slide 25: Patient with high recipient chimerism shows dramatic reduction after first infusion
Patient with high recipient chimerism post-transplant shows dramatic reduction following first infusion of TSC-101 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo AML-p53 MDS AML AML ALL-p53 MDS-p53 AML MDS AML MD
Slide 26: No patients in Cohort C have relapsed to date
No patients in Cohort C have relapsed to date, with higher rates of complete donor chimerism compared to control-arm patients Cohort A Cohort C Control Immediately post-HCT 37% (7/19) 14% (2/14) 24% (4/17) ~3 weeks after infusion 1 79% (15/19) 79% (11/14) 61% (11/18)# ~3 weeks after infusion 2 73% (
Slide 27: TSC-101 in Cohort C continues to show high levels of circulating TCR-T cells
TSC-101 in Cohort C continues to show high levels of circulating TCR-T cells TSC-101 in Cohort C TSC-101 in Cohort A TSC-101 levels following first infusion Time following first infusion (days) Data on file; Data as of June 8, 2026
Slide 28: Higher markers of proliferation, activation, and cytotoxicity in Cohort C
TSC-101 in Cohort C shows higher markers of proliferation, activation, and cytotoxicity than in Cohort A 2hr D7 CD28 (activation) is higher in Cohort C Granzyme B (cytotoxicity) is higher 7 days post infusion in Cohort C 2hr D7 Ki67 (proliferation) is higher in Cohort C 2hr D7 Data on file; Data as
Slide 29: 93% of Cohort C patients responded with decreasing recipient chimerism
All but one patient in Cohort C (93%) responded to TSC-101 with decreasing recipient chimerism % recipient chimerism % recipient chimerism Donor chimerism results using investigational next-generation sequencing assay (Alloheme) with data cut-off of 0.2% at indicated times post-transplant (# ± 3 day
Slide 30: Heme Program: Review of Cohort C Data
Heme Program: Review of Cohort C Data
Slide 31: Patients are generally well balanced across arms
Patients are generally well balanced across arms, although Cohort C included a higher percentage of patients with MRD-positive disease prior to transplant TSC-101 Cohort A TSC-101 Cohort C Control Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (6
Slide 32: 11 of 14 patients achieved complete donor chimerism within ~3 weeks
04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 16-003 27-004 13-017 13-019 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 27-004 16-003 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 11 of 14 patients achieved complete donor chimerism within ~3 weeks of
Slide 33: Heme Phase 3 trial design
Heme Phase 3 trial design Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 34: Pivotal trial design for TSC-101 uses a biologically-assigned control arm
Pivotal trial design for TSC-101 uses a biologically-assigned control arm to support relapse-free survival as the primary endpoint Biological assignment Two infusions of TSC-101 RIC-based transplant Study Population AML or MDS Age > 18 years Undergoing first allo-HCT Eligible for reduced intensity c
Slide 35: Important protocol modifications from Phase 1 to Phase 3 study
Important protocol modifications from Phase 1 to Phase 3 study Phase 1 Phase 3 Population AML, ALL, MDS AML, MDS Donor Type Haplo in Cohort A; Haplo and MMUD enrolled in Cohort C Haplo and MMUD Enrollment Ratio Treatment:Control ~1:1 Treatment:Control 1:1 with flexibility up to ~1.5:1 Enrollment Str
Slide 36: Strategies developed to achieve balance between treatment and control arms
Strategies developed to achieve balance between treatment and control arms Goal: Balanced enrollment of high-risk vs. intermediate/low risk subjects between treatment and control arms *Any TP53, inversion 3, t(3;3) participant; ^ Strata include disease (AML, MDS) and risk status Enrollment Stratific
Slide 37: US geographical footprint ensures appropriate patient access to treatment
US geographical footprint ensures appropriate patient access to treatment ~120 centers conduct allo-HCT 21 sites in Phase 1 clinical trial 30 sites in Phase 3 trial ATCs Color Coded by Category: Current clinical trial sites Potential additional sites for pivotal Potential additional sites for commer
Slide 38: Heme program: HLA and indication expansion
Heme program: HLA and indication expansion
Slide 39: CD45 is a lineage-specific antigen expressed in all hematopoietic cells
CD45 is a lineage-specific antigen with expression in all hematopoietic cells, including HSCs CD45 is a large protein with many well-known epitopes for high frequency HLAs Antigen-negative donors will be selected by mismatching on HLA (using haploidentical and MMUD donors) TCRs for additional HLA ty
Slide 40: INDs cleared for TSC-102-A03 and TSC-102-A01; Phase 1 planned for Q4 2026
INDs cleared for TSC-102-A03 and TSC-102-A01; Phase 1 planned for Q4 2026 Indications AML, ALL, MDS Non-Hodgkin Lymphoma Study Characteristics Dose escalation RIC or MAC Haplo or MMUD Study expands the heme program Two additional HLA types MAC conditioning ALL and Non-Hodgkin Lymphoma in addition to
Slide 41: Continuous data read-outs over the next two years provides clinical de-risking
Continuous data read-outs over the next two years provides clinical de-risking ALLOHA-2 Ph3 topline readout Cohort C early data Update on Cohort C data TSC-102 Ph1 trial initiation Update on Cohort C data 1-year data from TSC-102 ALLOHA-2 Phase 3 trial will take ~2 years, with a topline readout targ
Slide 42: Market opportunity
Market opportunity hee emnnrnes
Slide 43: TSC-101 is incorporated seamlessly into current transplant journey
TSC-101 is incorporated seamlessly into current transplant journey * Infusion 1 & 2 site of care (inpatient vs outpatient) determined by administering physician. Infusion 1 may be given upon engraftment and between days 14-35 post transplant, infusion 2 would be administered about 40 days after infu
Slide 44: At launch, ~2,350 patients will qualify for TSC-101 in the U.S.
At launch, ~2,350 patients will qualify for TSC-101 in the U.S. based on HLA type ~7,000 AML/MDS patients estimated to undergo Allo HCT in 2029* 2,940 HLA-A*02:01 positive patients (42%) 2,350 with A*02-negative donor (80%) Addressable U.S. Patient Population Requires transplant with reduced intensi
Slide 45: Market opportunity based on current transplant practice
Market opportunity based on current transplant practice Reduced intensity conditioning (RIC) Myeloablative conditioning (MAC) 4% 18% 45% 33% Haploidentical and mismatched unrelated donors (MMUDs) Matched unrelated donors (MUDs) Matched related donors (MRDs) Other 66% 34% Total transplants: ~2,350 pe
Slide 46: Expansion opportunity 1: Changes in clinical practice over time
Expansion opportunity 1: Positive data expected to induce changes in clinical practice over time that increase the on-label use of TSC-101 Total transplants: ~2,350 per year Reduced intensity conditioning (RIC) Myeloablative conditioning (MAC) 4% 63% 33% Haploidentical and mismatched unrelated donor
Slide 47: Positive data expected to increase use of RIC and haplo/MMUD donors
Positive data expected to increase use of RIC and haplo/MMUD donors # of addressable patients (US) Source: SEER, CIBMTR, EBMT, APBMT; RIC, reduced intensity conditioning; Haplo, haploidentical donor; MMUD, mismatched unrelated donor TSC-101 7,000 6,000 0 5,000 1,000 2,000 3,000 4,000 700 - 2,000
Slide 48: Expansion opportunity 2: Increased use of transplant
Expansion opportunity 2: Increased use of transplant provides a way to reach over 2,800 AML and MDS patients per year in the U.S. # of addressable patients (US) Source: SEER, CIBMTR, EBMT, APBMT; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes TSC-101 Transplant expansion +44% 7,000 6,00
Slide 49: Expansion opportunity 3: Additional HLAs more than double the patient population
Expansion opportunity 3: Products that address additional HLAs more than double the potential patient population # of addressable patients (US) Source: SEER, CIBMTR, EBMT, APBMT; HLA, human leukocyte antigen TSC-101 Transplant expansion 1,008 - 2,880 +44% 7,000 6,000 0 5,000 1,000 2,000 3,000 4,000
Slide 50: Q&A
Q&A
Slide 51: Appendix
Appendix -_
Slide 52: Heme Program: TSC-101 Cohort A chimerism data
Heme Program: TSC-101 Cohort A chimerism data
Slide 53: TSC-101 continues to show strong activity by chimerism assays
TSC-101 continues to show strong activity by chimerism assays DL1 DL2‡ DL2 DL3‡ DL3 DL3 DL3 DL3 DL3‡ DL3 DL3 DL3 DL3‡ DL3 DL4‡ DL3 DL4‡ DL4‡ DL4 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 MDS AML B-ALL B-ALL MDS AML AML MDS AML AML AML AML MDS AML AML AML AML MDS AML MDS
Slide 54: Market opportunity
Market opportunity hee emnnrnes
Slide 55: Relapse prevention in heme malignancies: a compelling opportunity
Relapse prevention in heme malignancies: a compelling opportunity Targeted Patient Population Clinical De-risking First-Mover Advantage Clear unmet need Able to target transplant centers where AML/MDS patients are treated TSC-101 is the first and only current product candidate designed to treat rela
Slide 56: US geographical footprint ensures appropriate patient access to treatment
US geographical footprint ensures appropriate patient access to treatment ~120 centers conduct allo-HCT 21 sites in Phase 1 clinical trial 30 sites in Phase 3 trial Targeting 40 ATCs at launch ATCs Color Coded by Category: Current clinical trial sites Potential additional sites for pivotal Potential
Slide 57: Success of novel therapies increases the number of patients eligible for transplant
Success of novel therapies increases the number of patients that may become eligible for transplant Induction Consolidation or R/R and Bridging Transplant R/R: Relapsed or refractory; Source: Beacon Cell Therapy Database, Evaluate Database, Company websites, corporate decks, and PRs; *Includes TKIs,
Slide 58: Physician hesitance around RIC and drivers of change in HCT rate
Physician hesitance around RIC is in part driven by data demonstrating higher relapse rates and lower overall survival in MRD+ patients receiving RIC (Hourigan. J Clin Oncol. 2020); Source: Physician Interviews; ClearView Analysis; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; HCT, he
Slide 59: TSC-101 expected U.S. pricing between $650K and $750K by 2029
TSC-101 is positioned in the U.S. for expected pricing between $650K and $750K by 2029 WAC $400K $500K $600K $700K $800K $900K $1M Volume tradeoffs for TSC-101 (Volume indexed to 100%) Indexed volume Payer access Institutional access ATC price-utilization (avg.) (considering both ATC oncologists and
Slide 60: Solid Tumors: in vivo-engineered multiplex TCR-T therapy
Solid Tumors Developing in vivo-engineered multiplex TCR-T therapy to overcome tumor heterogeneity
Slide 61: Lentiviral in vivo technology addresses key challenges of autologous TCR-T
Lentivirus Lentiviral in vivo technology addresses the key challenges of autologous TCR-T In vivo engineering solves the key challenges of autologous TCR-T approaches Lymphodepletion is not required Off-the-shelf (no patient-specific manufacturing); lentivirus prepared in large batches with signific
Slide 62: MAGE-A4 TCR delivered in vivo illustrates tumor clearance in mice
MAGE-A4 TCR delivered in vivo with targeted LVVs illustrate tumor clearance in PBMC engrafted mice implanted with NSCLC solid tumor cell line Implant Tumor Day 14 Day 0 Day 13 NCG, MHC DKO mice Readout: Tumor volume Dose with LVV Engraft PBMCs (1x10M) Day 50 Day 21 Dose with ex vivo TCR-T (2x20M >90
Slide 63: Autoimmunity: TargetScan platform to discover T-cell targets
Autoimmunity Deploying TargetScan platform to discover novel T-cell targets in autoimmune disorders
Slide 64: Ankylosing spondylitis is a debilitating autoimmune disorder driven by T-cells
Ankylosing spondylitis (AS) is a debilitating autoimmune disorder strongly driven by T-cells but with a poorly characterized autoantigen target landscape Primarily affects young males (Male-to-Female ratio: 2:1); ~6 million cases globally (2018), including ~550,000 in North America Common symptoms i
Slide 65: Micro-CT reveals bone remodeling in mice immunized with TScan-identified targets
Micro-CT reveals bone remodeling in the spine of mice immunized with TScan-identified targets PBS (-) control AS-T007 Aggrecan (+) control PBS (-) control AS-T007 Aggrecan (+) control Data presented at the Antigen-Specific Immune Tolerance (ASIT) Summit (March 5, 2026; Boston) Screening of additiona
TScan Therapeutics — Technical Presentation (June 2026) on 6ix